List of works - Nicolas Widmer

Benchmarking therapeutic drug monitoring software: a review of available computer tools

scientific article published on January 2013

Biases affecting injected doses of an experimental drug during clinical trials.

scientific article published on 16 July 2016

Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: results from a randomized controlled trial.

scientific article published on 9 October 2014

Comparison against current standards of a DNA aptamer for the label-free quantification of tobramycin in human sera employed for therapeutic drug monitoring

scientific article published on 30 June 2018

Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): an emerging role for drug blood level testing?

scientific article

Determination of imatinib (Gleevec) in human plasma by solid-phase extraction-liquid chromatography-ultraviolet absorbance detection.

scientific article published in April 2004

Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib

scientific article published on September 2010

Effect of Adherence on Pharmacokinetic/Pharmacodynamic Relationships of Oral Targeted Anticancer Drugs

scientific article published on 20 June 2017

Emergency and Disaster Preparedness of European Hospital Pharmacists: A Survey

scientific article published on 19 November 2019

Erlotinib: another candidate for the therapeutic drug monitoring of targeted therapy of cancer? A pharmacokinetic and pharmacodynamic systematic review of literature

scientific article published on February 2015

Example-based support vector machine for drug concentration analysis

scientific article

Full-scale simulations to improve disaster preparedness in hospital pharmacies

scientific article published on 02 July 2022

Functional consequence of MDR1 expression on imatinib intracellular concentrations

scientific article published in August 2003

Higher CNS Penetration-Effectiveness of Long-term Combination Antiretroviral Therapy Is Associated With Better HIV-1 Viral Suppression in Cerebrospinal Fluid

article

Imatinib metabolite profiling in parallel to imatinib quantification in plasma of treated patients using liquid chromatography-mass spectrometry.

scientific article

Imatinib plasma concentrations variability in oncologic patients

pharmacology book

Imatinib plasma levels: correlation with clinical benefit in GIST patients

scientific article published on 23 February 2010

Large-scale imatinib dose-concentration-effect study in CML patients under routine care conditions.

scientific article published on 26 April 2014

Long-term prospective population PK study in GIST patients--letter

scientific article published on 5 February 2013

Monitoring drug therapy.

scientific article

Multiplex ultra-performance liquid chromatography-tandem mass spectrometry method for simultaneous quantification in human plasma of fluconazole, itraconazole, hydroxyitraconazole, posaconazole, voriconazole, voriconazole-N-oxide, anidulafungin, and

scientific article

Médicaments et grossesse : modifications pharmacocinétiques et place du suivi thérapeutique pharmacologique

Oral imatinib treatment reduces early fibrogenesis but does not prevent progression in the long term.

scientific article published on 12 July 2005

Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics.

scientific article

Population Pharmacokinetics of Erlotinib in Patients With Non-small Cell Lung Cancer: Its Application for Individualized Dosing Regimens in Older Patients

scientific article published on 03 July 2020

Population pharmacokinetic modelling and evaluation of different dosage regimens for darunavir and ritonavir in HIV-infected individuals

scientific article published on 12 May 2014

Population pharmacokinetic study of gentamicin in a large cohort of premature and term neonates

scientific article

Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein

scientific article published in July 2006

Prediction of free imatinib concentrations based on total plasma concentrations in patients with gastrointestinal stromal tumours

scientific article published on April 2013

Prescription of Sedative Drugs During Hospital Stay: A Swiss Prospective Study.

scientific article

Quantification of the next-generation oral anti-tumor drugs dabrafenib, trametinib, vemurafenib, cobimetinib, pazopanib, regorafenib and two metabolites in human plasma by liquid chromatography-tandem mass spectrometry.

scientific article published on 8 February 2018

Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability

scientific article published on 6 May 2008

Representation of Medical Guidelines with a Computer Interpretable Model

Resistance reversal by RNAi silencing of MDR1 in CML cells associated with increase in imatinib intracellular levels

scientific article published on 12 April 2007

Response to Calcagno comment on "Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid".

scientific article published in October 2013

Review of therapeutic drug monitoring of anticancer drugs part 1--cytotoxics

scientific article

Review of therapeutic drug monitoring of anticancer drugs part two--targeted therapies

scientific article

Severe pustular eruption associated with imatinib and voriconazole in a patient with chronic myeloid leukemia

scientific article

Swiss Armed Forces deployment during the COVID-19 pandemic: militia pharmacy officers' roles and duties

scientific article published on 18 September 2020

Systematic review of population pharmacokinetic analyses of imatinib and relationships with treatment outcomes

scientific article published on April 2013

The Steps to Therapeutic Drug Monitoring: A Structured Approach Illustrated With Imatinib

scientific article published on 03 March 2020

Therapeutic Drug Monitoring of Targeted Anticancer Protein Kinase Inhibitors in Routine Clinical Use: A Critical Review

scientific article published on 01 February 2020

Therapeutic Drug Monitoring of Targeted Anticancer Therapy. Tyrosine Kinase Inhibitors and Selective Estrogen Receptor Modulators: A Clinical Pharmacology Laboratory Perspective

scholarly article published 2012

Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.

scientific article

Therapeutic drug monitoring in cancer--are we missing a trick?

scientific article

Therapeutic drug monitoring of imatinib: Bayesian and alternative methods to predict trough levels.

scientific article published on March 2012

Therapeutic drug monitoring of targeted anticancer therapy

scientific article published on 03 September 2015

Therapeutic drug monitoring: clinical practice

scientific article published in July 2008

Towards a new combination therapy for tuberculosis with next generation benzothiazinones

scientific article

Transition of care: A set of pharmaceutical interventions improves hospital discharge prescriptions from an internal medicine ward

scientific article published on 24 November 2016

Tyrosine kinase inhibitors concentration monitoring in chronic myeloid leukemia.

scientific article published on 13 January 2010

Validation and clinical application of a multiplex high performance liquid chromatography - tandem mass spectrometry assay for the monitoring of plasma concentrations of 12 antibiotics in patients with severe bacterial infections

scientific article published on 17 May 2020

Who is in charge of assessing therapeutic drug monitoring? The case of imatinib.

scientific article

[Principles of therapeutic drug monitoring]

scientific article published on 01 July 2008

siRNA-mediated knock-down of P-glycoprotein expression reveals distinct cellular disposition of anticancer tyrosine kinases inhibitors

scientific article

List of works by Nicolas Widmer

Benchmarking therapeutic drug monitoring software: a review of available computer tools

Biases affecting injected doses of an experimental drug during clinical trials.

Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: results from a randomized controlled trial.

Comparison against current standards of a DNA aptamer for the label-free quantification of tobramycin in human sera employed for therapeutic drug monitoring

Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): an emerging role for drug blood level testing?

Determination of imatinib (Gleevec) in human plasma by solid-phase extraction-liquid chromatography-ultraviolet absorbance detection.

Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib

Effect of Adherence on Pharmacokinetic/Pharmacodynamic Relationships of Oral Targeted Anticancer Drugs

Emergency and Disaster Preparedness of European Hospital Pharmacists: A Survey

Erlotinib: another candidate for the therapeutic drug monitoring of targeted therapy of cancer? A pharmacokinetic and pharmacodynamic systematic review of literature

Example-based support vector machine for drug concentration analysis

Full-scale simulations to improve disaster preparedness in hospital pharmacies

Functional consequence of MDR1 expression on imatinib intracellular concentrations

Higher CNS Penetration-Effectiveness of Long-term Combination Antiretroviral Therapy Is Associated With Better HIV-1 Viral Suppression in Cerebrospinal Fluid

Imatinib metabolite profiling in parallel to imatinib quantification in plasma of treated patients using liquid chromatography-mass spectrometry.

Imatinib plasma concentrations variability in oncologic patients

Imatinib plasma levels: correlation with clinical benefit in GIST patients

Large-scale imatinib dose-concentration-effect study in CML patients under routine care conditions.

Long-term prospective population PK study in GIST patients--letter

Monitoring drug therapy.

Multiplex ultra-performance liquid chromatography-tandem mass spectrometry method for simultaneous quantification in human plasma of fluconazole, itraconazole, hydroxyitraconazole, posaconazole, voriconazole, voriconazole-N-oxide, anidulafungin, and

Médicaments et grossesse : modifications pharmacocinétiques et place du suivi thérapeutique pharmacologique

Oral imatinib treatment reduces early fibrogenesis but does not prevent progression in the long term.

Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics.

Population Pharmacokinetics of Erlotinib in Patients With Non-small Cell Lung Cancer: Its Application for Individualized Dosing Regimens in Older Patients

Population pharmacokinetic modelling and evaluation of different dosage regimens for darunavir and ritonavir in HIV-infected individuals

Population pharmacokinetic study of gentamicin in a large cohort of premature and term neonates

Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein

Prediction of free imatinib concentrations based on total plasma concentrations in patients with gastrointestinal stromal tumours

Prescription of Sedative Drugs During Hospital Stay: A Swiss Prospective Study.

Quantification of the next-generation oral anti-tumor drugs dabrafenib, trametinib, vemurafenib, cobimetinib, pazopanib, regorafenib and two metabolites in human plasma by liquid chromatography-tandem mass spectrometry.

Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability

Representation of Medical Guidelines with a Computer Interpretable Model

Resistance reversal by RNAi silencing of MDR1 in CML cells associated with increase in imatinib intracellular levels

Response to Calcagno comment on "Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid".

Review of therapeutic drug monitoring of anticancer drugs part 1--cytotoxics

Review of therapeutic drug monitoring of anticancer drugs part two--targeted therapies

Severe pustular eruption associated with imatinib and voriconazole in a patient with chronic myeloid leukemia

Swiss Armed Forces deployment during the COVID-19 pandemic: militia pharmacy officers' roles and duties

Systematic review of population pharmacokinetic analyses of imatinib and relationships with treatment outcomes

The Steps to Therapeutic Drug Monitoring: A Structured Approach Illustrated With Imatinib

Therapeutic Drug Monitoring of Targeted Anticancer Protein Kinase Inhibitors in Routine Clinical Use: A Critical Review

Therapeutic Drug Monitoring of Targeted Anticancer Therapy. Tyrosine Kinase Inhibitors and Selective Estrogen Receptor Modulators: A Clinical Pharmacology Laboratory Perspective

Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.

Therapeutic drug monitoring in cancer--are we missing a trick?

Therapeutic drug monitoring of imatinib: Bayesian and alternative methods to predict trough levels.

Therapeutic drug monitoring of targeted anticancer therapy

Therapeutic drug monitoring: clinical practice

Towards a new combination therapy for tuberculosis with next generation benzothiazinones

Transition of care: A set of pharmaceutical interventions improves hospital discharge prescriptions from an internal medicine ward

Tyrosine kinase inhibitors concentration monitoring in chronic myeloid leukemia.

Validation and clinical application of a multiplex high performance liquid chromatography - tandem mass spectrometry assay for the monitoring of plasma concentrations of 12 antibiotics in patients with severe bacterial infections

Who is in charge of assessing therapeutic drug monitoring? The case of imatinib.

[Principles of therapeutic drug monitoring]

siRNA-mediated knock-down of P-glycoprotein expression reveals distinct cellular disposition of anticancer tyrosine kinases inhibitors